Phase 3 Recruiting Network
This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs? This study would like to find out if this approach is better o…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06592924
Sites in South Carolina: - Medical University of South Carolina — Charleston, South Carolina
- Levine Cancer Institute-Rock Hill — Rock Hill, South Carolina
Phase 3 Recruiting Network
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03678025
Sites in South Carolina: - Prisma Health Cancer Institute - Spartanburg — Boiling Springs, South Carolina
- Medical University of South Carolina — Charleston, South Carolina
- Prisma Health Cancer Institute - Faris — Greenville, South Carolina
- Saint Francis Cancer Center — Greenville, South Carolina
- Prisma Health Cancer Institute - Eastside — Greenville, South Carolina
Phase 3 Recruiting Industry
This study will explore whether a combination of the investigational drug mevrometostat (PF-06821497) and enzalutamide will work better than taking enzalutamide alone in participants with mCSPC who are ARPI naïve and have not yet received …
Sponsor: Pfizer
NCT ID: NCT07028853
Sites in South Carolina: - Grand Strand Medical Center — Myrtle Beach, South Carolina
- Carolina Urologic Research Center, LLC — Myrtle Beach, South Carolina
- Parkway Surgery Center — Myrtle Beach, South Carolina
Phase 3 Recruiting Industry
The purpose of this study is to assess the efficacy and safety of opevesostat plus hormone replacement therapy (HRT) compared to alternative abiraterone acetate or enzalutamide in participants with Metastatic Castration-resistant Prostate …
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136650
Sites in South Carolina: - Ralph H. Johnson VA Health Care System (RHJVAHCS)-Urology ( Site 0083) — Charleston, South Carolina
Phase 3 Recruiting Industry
The purpose of this study is to compare the efficacy and safety of BMS-986365 versus the investigator's choice of therapy in participants with Metastatic Castration-resistant Prostate Cancer.
Sponsor: Celgene
NCT ID: NCT06764485
Sites in South Carolina: - Hollings Cancer Center — Charleston, South Carolina
- Carolina Urologic Research Center, LLC — Myrtle Beach, South Carolina
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the overall survival (length of time from the start of study to date of death from any cause) for pasritamig (JNJ-78278343) in combination with best supportive care (BSC) as compared to placebo with…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07164443
Sites in South Carolina: - Ralph H Johnson Veterans Hospital — Charleston, South Carolina
- Gibbs Cancer Center and Research Institute Pelham — Greer, South Carolina
- Carolina Urologic Research Center — Myrtle Beach, South Carolina
- Gibbs Cancer Center — Spartanburg, South Carolina
Phase 3 Recruiting Academic/Other
This phase III trial tests whether high-dose vitamin D works in treating androgen-deprivation therapy (ADT)-induced bone loss in patients with prostate cancer who are undergoing androgen-deprivation therapy. Vitamins are substances that th…
Sponsor: University of Rochester
NCT ID: NCT05838716
Sites in South Carolina: - Gibbs Cancer Center-Gaffney — Gaffney, South Carolina
- Saint Francis Hospital — Greenville, South Carolina
- Saint Francis Cancer Center — Greenville, South Carolina
- Gibbs Cancer Center-Pelham — Greer, South Carolina
- Spartanburg Medical Center — Spartanburg, South Carolina
Phase 3 Recruiting Industry
The purpose of this study is to find out whether treatment with pasritamig and docetaxel prolongs radiographic progression free survival (rPFS) (the length of time from start of treatment until disease worsens as determined by scans) when …
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07225946
Sites in South Carolina: - Carolina Urologic Research Center — Myrtle Beach, South Carolina
Phase 3 Recruiting Industry
This study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide will work better than taking enzalutamide alone in participants with mCRPC who are ARSi or abiraterone naïve.
Sponsor: Pfizer
NCT ID: NCT06629779
Sites in South Carolina: - AUC Urologists, LLC — Myrtle Beach, South Carolina
- Carolina Urologic Research Center, LLC — Myrtle Beach, South Carolina
- Grand Strand Medical Center — Myrtle Beach, South Carolina
- Parkway Surgery Center — Myrtle Beach, South Carolina
Phase 3 Recruiting Industry
This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) with respect to overall survival (OS) i…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136624
Sites in South Carolina: - Ralph H. Johnson VA Health Care System (RHJVAHCS)-Urology ( Site 0083) — Charleston, South Carolina
Phase 3 Recruiting Industry
This is a prospective, open-label Phase 3 study to evaluate copper Cu 64 PSMA I\&T injection for PET/CT imaging in patients with newly diagnosed unfavorable intermediate high-risk, high-risk or very high-risk prostate cancer.
Sponsor: Curium US LLC
NCT ID: NCT06235151
Sites in South Carolina: - Hollings Cancer Center — Charleston, South Carolina
- Carolina Urologic Research Center, LLC — Myrtle Beach, South Carolina
Phase 3 Recruiting Industry
The purpose of the study is to demonstrate superiority of Saruparib (AZD5305) relative to placebo added to a standard radiation therapy (RT) + androgen deprivation therapy (ADT) regimen by assessment of metastases-free survival in particip…
Sponsor: AstraZeneca
NCT ID: NCT06952803
Sites in South Carolina: - Research Site — Myrtle Beach, South Carolina
Phase 2, Phase 3 Recruiting Industry
This is a Phase II/III study. Patient population is adult participants with PSMA-positive mCRPC who had treatments with androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy and progressed on or after \[177Lu\]Lu-PSMA ta…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT06780670
Sites in South Carolina: - Carolina Urologic Research Center — Myrtle Beach, South Carolina
Phase 3 Recruiting Industry
The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.
Sponsor: Clarity Pharmaceuticals Ltd
NCT ID: NCT06056830
Sites in South Carolina: - Carolina Urologic Research Center — Myrtle Beach, South Carolina
Phase 3 Recruiting Industry
The intention of the study is to demonstrate superiority of AZD2265 relative to standard of care treatments by assessment of radiographic progression-free survival (rPFS) and overall survival (OS) in participants with mCRPC.
Sponsor: AstraZeneca
NCT ID: NCT07611110
Sites in South Carolina: - Research Site — Myrtle Beach, South Carolina
Phase 2 Recruiting NIH
This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03866382
Sites in South Carolina: - Medical University of South Carolina — Charleston, South Carolina
Phase 2 Recruiting Academic/Other
This phase II trial evaluates whether genetic testing in prostate cancer is helpful in deciding which study treatment patients are assigned. Patient cancer tissue samples are obtained from a previous surgery or biopsy procedure and tested …
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06632977
Sites in South Carolina: - Gibbs Cancer Center-Gaffney — Gaffney, South Carolina
- Gibbs Cancer Center-Pelham — Greer, South Carolina
- Spartanburg Medical Center — Spartanburg, South Carolina
- SMC Center for Hematology Oncology Union — Union, South Carolina
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311/BNT324 in subjects with advanced solid tumors.
Sponsor: DualityBio Inc.
NCT ID: NCT05914116
Sites in South Carolina: - Research Site 123 — Charleston, South Carolina
- Research Site 108 — Greenville, South Carolina
Phase 1, Phase 2 Recruiting Industry
Assessment of the safety and efficacy of HLD-0915 in patients with metastatic prostate cancer who have progressed on prior systemic therapies, with further evaluation in additional prostate cancer populations.
Sponsor: Halda Therapeutics OpCo, Inc.
NCT ID: NCT06800313
Sites in South Carolina: - Carolina Urologic Research Center, LLC — Myrtle Beach, South Carolina
Phase 2 Recruiting Industry
Hormone therapy, or androgen deprivation therapy (ADT) is a standard way to treat prostate cancer. It works by reducing the amount of the main male sex hormone, testosterone in the body. Androgen receptor pathway inhibitors (ARPIs) are ano…
Sponsor: Astellas Pharma Global Development, Inc.
NCT ID: NCT07005154
Sites in South Carolina: - Carolina Urologic Research Center — Myrtle Beach, South Carolina
Phase 2 Recruiting Industry
Phase 2a, open-label, multi-center study evaluating biomarkers and biodistribution of aglatimagene besadenovec plus valacyclovir in men with localized, intermediate-risk prostate cancer who are planning to receive external beam radiation t…
Sponsor: Candel Therapeutics, Inc.
NCT ID: NCT07332000
Sites in South Carolina: - START Carolinas — Myrtle Beach, South Carolina
Phase 2 Recruiting Federal
The purpose of this study is to learn about how an investigational drug intervention completed before doing prostate surgery (specifically, radical prostatectomy with lymph node dissection) may help in treatment of high risk localized pros…
Sponsor: VA Office of Research and Development
NCT ID: NCT05593497
Sites in South Carolina: - Ralph H. Johnson VA Medical Center, Charleston, SC — Charleston, South Carolina
Phase 2 Recruiting Industry
The goal of this clinical trial is to learn if the vaccine FK-PC101 works to delay or prevent the return of prostate cancer in men who have had surgery to remove their prostate cancer. It will also learn about the safety of FK-PC101. The m…
Sponsor: Cellvax Therapeutics Inc
NCT ID: NCT06636682
Sites in South Carolina: - Carolina Urologic Research Center — Myrtle Beach, South Carolina
Phase 2 Recruiting Academic/Other
This study will evaluate whether simvastatin reduces intraprostatic immunosuppressive microenvironment through YAP-mediated T-reg dysfunction, and increases intraprostatic anti-tumor immune response in men recently diagnosed with localized…
Sponsor: Medical University of South Carolina
NCT ID: NCT05586360
Sites in South Carolina: - Hollings Cancer Center at Medical University of South Carolina — Charleston, South Carolina
Phase 1, Phase 2 Recruiting Academic/Other
The purpose of this Phase I/II study is to determine the safety and effectiveness of up to 5 study drugs used together for the treatment of solid tumor cancers. The drugs are hydroxychloroquine, metformin, sirolimus, dasatinib and nelfinav…
Sponsor: Medical University of South Carolina
NCT ID: NCT05036226
Sites in South Carolina: - Medical University of South Carolina — Charleston, South Carolina